Study offering new hope for medical presbyopia correction.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      The article presents results of the BRIO-I study, a clinical trial of Brimochol PF, a topical fixed-dose combination for the treatment of presbyopia from Visus Therapeutics, which references a research paper by R. S. Verhoeven et al., published in a 2022 issue of the "Investigative Ophthalmology & Visual Science." It discusses a comparison of a single dose of the drug with individual monotherapies, and the implications of the study for future medical presbyopia correction.